Anticoagulant-related gastrointestinal bleeding-could this facilitate early detection of benign or malignant gastrointestinal lesions?

Annals of Medicine

Volumn 46, Issue 8, 2014, Pages 672-678

  Clemens, Andreas ^a,b   Strack, Andreas ^c   Noack, Herbert ^b   Konstantinides, Stavros ^a   Brueckmann, Martina ^b,d   Lip, Gregory Y H ^e  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c Marien Hospital Darmstadt   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Anticoagulants; Gastrointestinal hemorrhage; Gastrointestinal neoplasms; Non vitamin K oral anticoagulants

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; THIOPHENE DERIVATIVE;

ANTICOAGULATION; ANUS CANCER; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CLINICAL TRIAL; COLON CANCER; DIGESTIVE SYSTEM INJURY; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG INDUCED DISEASE; EARLY DIAGNOSIS; ESOPHAGUS CANCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TUMOR; HEART ATRIUM FIBRILLATION; HUMAN; STOMACH CANCER; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; COMPLICATION; GASTROINTESTINAL NEOPLASMS; INCIDENCE; PHASE 3 CLINICAL TRIAL (TOPIC); RETROSPECTIVE STUDY;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CLINICAL TRIALS, PHASE III AS TOPIC; EARLY DETECTION OF CANCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL NEOPLASMS; HUMANS; INCIDENCE; MORPHOLINES; PYRAZOLES; PYRIDONES; RETROSPECTIVE STUDIES; THIOPHENES; WARFARIN;

EID: 84919389261     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2014.952327     Document Type: Article

References (52)

1. Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ. 2006; 333: 726.
2. Ghate SR, Biskupiak J, Ye X, Kwong WJ, Brixner DI. All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation. J Manag Care Pharm. 2011; 17: 672-84.
3. Guerrouij M, Uppal CS, Alklabi A, Douketis JD. The clinical impact of bleeding during oral anticoagulant therapy: assessment of morbidity, mortality and post-bleed anticoagulant management. J Thromb Thrombolysis. 2011; 31: 419-23.
4. Barada K, Abdul-Baki H, El Hajj II, Hashash JG, Green P H. Gastrointestinal bleeding in the setting of anticoagulation and antiplatelet therapy. J Clin Gastroenterol. 2009; 43: 5-12.
5. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993; 95: 315-28.
6. Asiimwe A, Li JJ, Weerakkody G, Vangerow H, Delisle F, Benoit K, et al. Diagnoses of gastrointestinal cancers after gastrointestinal bleeding in patients receiving clopidogrel or warfarin. Curr Drug Saf. 2013; 8: 261-9.
7. Jaffin BW, Bliss CM, LaMont JT. Significance of occult gastrointestinal bleeding during anticoagulation therapy. Am J Med. 1987; 83: 269-72.
8. Michaels M M. Bleeding from occult tumors during anticoagulant therapy. Circulation. 1962; 25: 804-6.
9. Norton SA, Armstrong C P. Lower gastrointestinal bleeding during anticoagulant therapy: a life-saving complication? Ann R Coll Surg Engl. 1997; 79: 38-9.
10. Bloom BJ, Filion KB, Atallah R, Eisenberg MJ. Meta-analysis of randomized controlled trials on the risk of bleeding with dabigatran. 2014; 113: 1066-74.
11. Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, Nessel CC, et al. Factors associated with major bleeding events: insights from the ROCKET AF Trial (Rivaroxaban Once-daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol. 2014; 63: 891-900.
12. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011; 123: 2363-72.
13. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-92.
14. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883-91.
15. Gallagher AM, van Staa TP, Murray-Thomas T, Schoof N, Clemens A, Ackermann D, et al. Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes. BMJ Open. 2014; 4: e003839.
16. Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke. 2012; 43: 1511-17.
17. Wei H, Shang J, Keohane C, Wang M, Li Q, Ni W, et al. A novel approach to assess the spontaneous gastrointestinal bleeding risk of antithrombotic agents using Apc(min/-) mice. Thromb Haemost. 2014; 111: 1121-32.
18. Merck Manual. Colorectal cancer. Available at: http://www.merckmanuals. com/home/digestive-disorders/tumors-of-the-digestive-system/colorectal-cancer.html (accessed 23 January 2014).
19. RE-LY (ClinicalTrials.gov). Randomized evaluation of long term anticoagulant therapy (RE-LY) with dabigatran etexilate. Available at: http://clinicaltrials.gov/ct2/show/results/NCT00262600?term=dabigatran &recr=Completed &rslt=With &cond=atrial + fibrillation &phase=123 &rank=3 §=X43015 (accessed 21 January 2014).
20. R OCKET AF (ClinicalTrials.gov). A n efficacy and safety study of rivaroxaban with warfarin for the prevention of stroke and non-central nervous system systemic embolism in patients with non-valvular atrial fibrillation. Available at: http://clinicaltrials.gov/ct2/show/results/NCT0 0403767?term=rivaroxaban &recr=Completed &rslt=With &cond=atrial + fibrillation &phase=123 &rank=1 (accessed 21 January 2014).
21. A RISTOTLE (ClinicalTrials.gov). A pixaban for the prevention of stroke in subjects with atrial fibrillation (ARISTOTLE). Available at: http://clinicaltrials.gov/ct2/show/results/NCT00412984?term=apixaban &recr=Completed &rslt=With &cond=atrial + fibrillation &phase=123 &rank=1 §=X43015 (accessed 21 January 2014).
22. EngageAFTIMI48 (ClinicalTrials.gov). Global study to assess the safety and effectiveness of edoxaban (DU-176b) vs standard practice of dosing with warfarin in patients with atrial fibrillation (EngageAFTIMI48). Available at: http://clinicaltrials.gov/ct2/show/NCT00781391?term=edoxaban &recr=Completed &cond=atrial + fibrillation &rank=1 (accessed 21 January 2014).
23. Bytzer P, Connolly SJ, Yang S, Ezekowitz M, Formella S, Reilly PA, et al. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol. 2013; 11: 246-52.
24. Banke IJ, Arlt MJ, Mueller MM, Sperl S, Stemberger A, Sturzebecher J, et al. effective inhibition of experimental metastasis and prolongation of survival in mice by a potent factor Xa-specific synthetic serine protease inhibitor with weak anticoagulant activity. Thromb Haemost. 2005; 94: 1084-93.
25. Mousa SA, Linhardt R, Francis JL, Amirkhosravi A. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb Haemost. 2006; 96: 816-21.
26. Akl EA, Kamath G, Kim SY, Yosuico V, Barba M, Terrenato I, et al. Oral anticoagulation may prolong survival of a subgroup of patients with cancer: a Cochrane systematic review. J Exp Clin Cancer Res. 2007; 26: 175-84.
27. Cunningham MS, Preston RJ, O'Donnell JS. Does antithrombotic therapy improve survival in cancer patients? Blood Rev. 2009; 23: 129-35.
28. Letai A, Kuter DJ. Cancer, coagulation, and anticoagulation. Oncologist. 1999; 4: 443-9.
29. Zacharski LR, Henderson WG, Rickles FR, Forman WB, Cornell CJ Jr, Forcier RJ, et al. effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer. 1984; 53: 2046-52.
30. Kuderer NM, Ortel TL, Francis CW. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol. 2009; 27: 4902-11.
31. Apixaban CDER review. Center for drug evaluation and research pharmacology reviews. Available at: http://www.accessdata.fda.gov/drugsatfda- docs/nda/2012/202155Orig1s000PharmR.pdf (accessed 2 May 2014).
32. Dabigatran SmPC. Pradaxa summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/000829/WC500041059. pdf (accessed 2 March 2014).
33. Rivaroxaban EPAR. C ommittee for medicinal products for human use assessment report. Available at: http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Assessment-Report-Variation/human/000944/WC500120736.pdf (accessed 2 May 2014).
34. Tsopanoglou NE, Maragoudakis ME. Role of thrombin in angiogenesis and tumor progression. Semin Thromb Hemost. 2004; 30: 63-9.
35. Wu C-W, Sung JJ-Y. Colorectal cancer screening: are stool and blood based tests good enough? Chin Clin Oncol. 2013; 2: 8.
36. Holme ∅, Bretthauer M, Fretheim A, Odgaard-Jensen J, Hoff G. Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. Cochrane Database of Systematic Reviews. Available at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009259.pub2/references. (Accessed 6 March 2014).
37. Kershenbaum A, Flugelman A, Lejbkowicz F, Arad H, Rennert G. Excellent performance of Hemoccult Sensa in organised colorectal cancer screening. Eur J Cancer. 2013; 49: 923-30.
38. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996; 348: 1472-7.
39. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecaloccult-blood test. Lancet. 1996; 348: 1467-71.
40. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993; 328: 1365-71.
41. Shaukat A, Mongin SJ, Geisser MS, Lederle FA, Bond JH, Mandel JS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med. 2013; 369: 1106-14.
42. Jorgensen OD, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut. 2002; 50: 29-32.
43. Clarke P, Jack F, Carey FA, Steele RJ. Medications with anticoagulant properties increase the likelihood of a negative colonoscopy in faecal occult blood test population screening. Colorectal Dis. 2006; 8: 389-92.
44. Sawhney MS, McDougall H, Nelson DB, Bond JH. Fecal occult blood test in patients on low-dose aspirin, warfarin, clopidogrel, or nonsteroidal anti-inflammatory drugs. Dig Dis Sci. 2010; 55: 1637-42.
45. Konrad G, Katz A. Are medication restrictions before FOBT necessary? Practical advice based on a systematic review of the literature. Can Fam Physician. 2012; 58: 939-48.
46. Mandelli G, Radaelli F, Paggi S, Terreni N, Gola G, Gramegna M, et al. Anticoagulant or aspirin treatment does not affect the positive predictive value of an immunological fecal occult blood test in patients undergoing colorectal cancer screening: results from a nested in a cohort case-control study. Eur J Gastroenterol Hepatol. 2011; 23: 323-6.
47. Ashraf I, Paracha S, Paracha S, Arif M, Choudhary A, Godfrey JD, et al. Antithrombotics during fecal occult blood testing: a meta-analysis and systematic review. The Internet Journal of Gastroenterology. 2013; 13.
48. Bujanda L, Sarasqueta C, Lanas A, Quintero E, Cubiella J, Hernandez V, et al. effect of oral anticoagulants on the outcome of faecal immunochemical test. Br J Cancer. 2014; 110: 1334-7.
49. Goss AM, van Ryn J, Schurer J, Clemens A. Assessment of crossreactivity in three different fecal occult blood test systems with dabigatran and dabigatran etexilate: identification of useful test methods. Blood. 2012; 120: Abstr 4360.
50. Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost. 2012; 107: 838-47.
51. Johannsdottir GA, Onundarson PT, Gudmundsdottir BR, Bjornsson ES. Screening for anemia in patients on warfarin facilitates diagnosis of gastrointestinal malignancies and pre-malignant lesions. Thromb Res. 2012; 130: e20-e25.
52. Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer Systematic review and meta-analysis. Ann Intern Med. 2014; 160: 171-81.